Handelsavisen
prelaunch
Companies ›Healthcare ›300039.SZ
30
300039.SZ — Shenzhen Stock Exchange Pharmaceuticals

Shanghai Kaibao Pharmaceutical Co Ltd

¥5,41
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,95 %
Op margin
28,2 %
ROE
6,3 %
Net margin
24,2 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Shanghai Kaibao Pharmaceutical Co Ltd is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily in the Chinese market.

Business. Shanghai Kaibao Pharmaceutical Co Ltd (300039.SZ) is a pharmaceutical company headquartered in Shanghai, China. The firm operates within the healthcare sector, specifically focusing on the development and sale of pharmaceutical products. It is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
6,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300039.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300039.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Shanghai Kaibao Pharmaceutical Co Ltd (300039.SZ) is a pharmaceutical company headquartered in Shanghai, China. The firm operates within the healthcare sector, specifically focusing on the development and sale of pharmaceutical products. It is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Shanghai Kaibao Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 13.41, indicating that the company holds significantly more current assets than current liabilities. The company is effectively managing its capital structure, as evidenced by a debt-to-equity ratio of 0.0, suggesting no long-term debt obligations.

    In terms of profitability, the company's return on equity (ROE) is 6.31%, and its return on assets (ROA) is 5.83%. These figures are in line with the typical performance metrics for the pharmaceutical industry, which often emphasize stable returns and long-term growth.

    The company's revenue is primarily concentrated in its domestic market, with no disclosed international segments. This geographic concentration may expose the company to regional economic fluctuations and regulatory changes in China.

    Looking at the growth trajectory, the company has demonstrated consistent revenue and net income growth. However, the exact numeric deltas for the current and next fiscal years are not provided in the available data. The company's operating cash flow of 230.74 million CNY and free cash flow of 149.95 million CNY indicate a healthy cash generation capability.

    The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of net cash being negative after subtracting total debt suggests a need for careful monitoring of short-term liquidity. However, the absence of long-term debt and the high current ratio mitigate some of these concerns.

    Recent events and filings have not been disclosed in the available data, so no specific recent developments can be cited at this time.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 13.41.
    • It maintains a debt-free capital structure, as indicated by a debt-to-equity ratio of 0.0.
    • The company's ROE and ROA are in line with industry norms, suggesting stable profitability.
    • Revenue is concentrated in the domestic market, which may pose regional exposure risks.
    • The company generates significant operating and free cash flows, supporting its financial health.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥5,41
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    ¥4.42B
    Net cashⓘ
    -¥6.2M
    Current ratioⓘ
    13.4
    Debt / equityⓘ
    0.0
    ROAⓘ
    5.8%
    ROEⓘ
    6.3%
    Cash conversionⓘ
    83.0%
    CapEx / revenueⓘ
    -2.4%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin28,2 %Best in class
    Net Margin24,2 %Above P75
    ROE6,3 %Above median
    Capex / Rev-2,4 %Above median
    D/E0,00Above P75
    Cash Conv0,83Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Shanghai Kaibao Pharmaceutical Co Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300039.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage